



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12Q 1/68, C12N 15/12	A1	(11) International Publication Number: WO 95/06137 (43) International Publication Date: 2 March 1995 (02.03.95)
(21) International Application Number: PCT/AU94/00506 (22) International Filing Date: 29 August 1994 (29.08.94) (30) Priority Data: PM 0859 27 August 1993 (27.08.93) AU (71) Applicants (for all designated States except US): AUSTRALIAN RED CROSS SOCIETY [AU/AU]; 480 Queen Street, Brisbane, QLD 4000 (AU). THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH [AU/AU]; The Bancroft Centre, 300 Herston Road, Brisbane, QLD 4029 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only): HYLAND, Catherine, Agnes [AU/AU]; 10 Lossock Avenue, Camp Hill, QLD 4152 (AU). WOLTER, Lindsay, Colin [AU/AU]; 8 Brescia Street, Holland Park, QLD 4121 (AU). SAUL, Allan [AU/AU]; 14 Dajarra Street, The Gap, QLD 4061 (AU). (74) Agent: KELLY, Robin, Thomas; Fisher & Kelly, Level One, 349 Coronation Drive, Milton, QLD 4064 (AU).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD). Published <i>With international search report.</i>
(54) Title: DETECTION OF GENES		
(57) Abstract <p>A process for detection of one of a number of closely related genes including the steps of: (i) carrying out a PCR assay including one or more DNA test samples from a human, animal or plant DNA cell extract in combination with at least one reference standard which includes a DNA cell extract having a first gene normally found in such DNA cell extract in a copy number of 1 or more per cell and a second gene closely related to the first gene but usually present in the DNA cell extract in a copy number of 0, 1, 2 or more together with a first primer specific for said first gene, a second primer specific for said second gene and a third primer common to both the first gene and the second gene; and (ii) determining the presence of the second gene in said DNA test sample(s) by comparison of the test sample(s) with said at least one reference standard.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

TITLE

DETECTION OF GENES

FIELD OF INVENTION

THIS INVENTION relates to detection of genes and
5 in particular detection of one of a number of closely
related genes which usually will have their respective
sequences already determined, although this is not
essential.

The invention may be primarily directed at genes
10 which are present in human cells although this is not
the only application of the invention and thus the
invention may be directed to genes present in animal
cells or in plant cells.

The invention however has particular relevance to
15 detection of rhesus (Rh) D blood group antigens and
thus may be utilised for rhesus D genotyping.

BACKGROUND ART

The rhesus blood group antigens are clinically
important because of their highly immunogenic nature.
20 Specifically they are central in the pathogenesis of
Rh haemolytic disease of the new born (HDN) and some
autoimmune haemolytic anemias. Furthermore in blood
transfusion it is important to avoid immunisation of
Rh-negative recipients, particularly women, with Rh-
25 positive blood and to avoid transfusion of immunised
patients with Rh- incompatible blood products. There
are five most commonly typed Rh antigens: C/c, E/e
and the D antigen which is the most immunogenic,
defining an individual as Rh-positive or Rh-negative.
30 Previously it was hypothesised that RhD may have an
alternative allelic gene which was designated (d);
however, Southern analysis has since shown that RhD
negative phenotypes result from the absence of RhD
genes that code for the D antigen as described in
35 Colin et al Blood 78:2747 (1991). In other words RhD-
positive individuals have either one or two RhD genes
per cell and RhD-negative individuals have no RhD

genes at all.

RhD typing was initially performed by agglutination with human polyclonal anti-D sera but has recently progressed to agglutination with IgM and/or blends or IgM and IgG anti-D monoclonal antibodies. However, even these monoclonal antibodies may not detect some weak RhD antigens and RhD variants. Additionally these serological techniques only allow a probable RhD genotype (one or two D genes) to be assigned based on Rh phenotype and available population statistical data. Often unambiguous RhD genotypic information is required such as in the case of prenatal counselling of Rh-negative mothers previously immunised with an Rh-positive child.

Reference may also be made to Lo *et al.* Vol 341 1147-1148 of the Lancet (1993) wherein a prenatal determination of fetal RhD status by analysis of peripheral blood of rhesus negative mothers was carried out. In this reference the authors utilised firstly the sequence of the recently cloned RhD gene (Le Van Kim *et al.* Proc Natl Acad. Sci USA (1992) 89 10925-29), and secondly the observation that RhD negative individuals lack this gene (Colin *et al.* Blood 78 2747 1991). Lo *et al.* therefore designated a PCR assay to detect RhD DNA sequences from a RhD-positive fetus by amplification from the peripheral blood of RhD-negative mothers.

In the Lo *et al.* assay the controls utilised were a 1 in 10⁵ dilution of 1 µg homozygous RhD-positive DNA in 5 µg RhD-negative male DNA as a positive control and water as a negative control. The other samples assayed were clinical samples from patients as well as 5 µg RhD-negative male DNA. The marker utilised was pBR322 DNA digested with HaeIII.

In the Lo *et al.* PCR assay PCR primers were designed to amplify regions outside the coding

sequence for the D gene at the 3' end. They did this because the Rh CE gene and D genes are very closely related. They therefore chose the 3' non coding region of the D gene which differs from the CE gene.

5 They therefore did not amplify the CE gene at all.

In the PCR assay PCR products were analysed by agarose gel electrophoresis. However, this PCR assay could only indicate the presence or absence of the RhD gene in the sample tested and could not be utilised for

10 quantifying the number of RhD genes present (ie. one or two genes). The inability to quantify the number or dosage of RhD genes present means that a true RhD genotype of an individual could not be assigned.

Reference also may be made to Arce *et al.* Blood 82 651-655 (1993) which refers to molecular cloning of RhD cDNA derived from a gene present in RhD positive, but not RhD negative individuals as well as Bennett *et al.* The New England Journal of Medicine, Aug 26 (1993) 607-610 which refers to prenatal determination of

15 20 fetal RhD type by DNA amplification. Both these references identify the D gene but do not give a D gene dosage unlike the present invention.

In the Bennett *et al.* reference two pairs of primers are produced wherein a first pair of primers

25 amplify a 136 bp region common to the RhCcEe and RhD genes (i.e. exon 7) and the second pair of primers amplify a 186 bp region specific to the 3' untranslated sequence (exon 10) of the RhD gene. The two amplification reactions are performed in the same

30 tube. Only the 136 bp product is amplified from RhD negative DNA whereas both the 136 bp and 186 bp products are amplified from RhD positive DNA.

The Arce *et al.* reference amplifies a region of the D gene known as "exon 4 to 5" by experiments

35 carried out by the inventor(s). It has also been established that the exon 10 method gives more false positives than exon 7. It has also been established

that PCR of exon 4 to 5 is also subject to false positives and is hard to perform.

SUMMARY OF THE INVENTION

5 It therefore is an object of the invention to provide a process and apparatus for detection of one or a number of closely related genes which is efficient and which may alleviate to at least a certain extent the disadvantages described above in relation to conventional detection of RhD antigens.

10 The invention is therefore relevant to a situation involving closely related genes involving a first gene which is normally found in cells in at least 1 copy number per cell and a second gene which may be present in cells in 0, 1, 2 or more copy
15 numbers per cell and it is desired to detect the presence of the second gene in human, animal and plant cells. In the specific example referred to above the CcEe gene is normally present in humans in 2 copy numbers per cell and the RhD gene may be present in 0,
20 1 or 2 copy numbers per cell.

In another example D variant genes may usually be present in a copy number of 0 or 1 per cell and therefore the invention may be applicable to detection of either the RhD gene or RhD variant gene using the
25 CcEe gene as an appropriate control.

While the invention has particular relevance to genes which have had their nucleotide sequence already determined it also has relevance to genes which have yet to have their nucleotide sequence determined
30 provided that such genes will be found to be closely related in nucleotide sequence at a later date.

The process of the invention may therefore include the following steps:

- 35 (i) carrying out a PCR assay including one or more DNA test samples from a human, animal or plant DNA cell extract in combination with at least one reference standard which

includes a DNA cell extract having a first gene normally found in such DNA cell extract in a copy number of 1 or more per cell and a second gene closely related to the first gene but usually present in the DNA cell extract in a copy number of 0, 1, 2 or more together with a first primer specific for said first gene, a second primer specific for said second gene and a third primer common to both the first gene and the second gene; and

(ii) determining the presence of the second gene in said DNA test sample(s) by comparison of the test sample(s) with said at least one reference standard.

Preferably in the process of the invention there are included as many reference standards to correspond with the variation in copy number of the second gene.

Usually the first gene is fixed or constant among individuals in comparison to the second gene which may be variable.

The invention may also include as a preferred embodiment in regard to step (ii) not only detection of the second gene but also quantification of the second gene (ie. specifying the copy number of the second gene per cell).

The process of the invention may also be directed to the detection of one of a number of closely related genes in cell extracts and thus include detection of the second gene or another gene closely related to the second gene (which may be a mutation of the second gene).

In specific reference to RhD genotyping the first gene may correspond to the CcEe gene (which is normally present in a copy number of 2 per cell) and the second gene may correspond to the RhD gene or RhD gene variants.

The PCR assay may be carried out using as an enzyme component a source of thermostable DNA polymerase suitably comprising Taq DNA polymerase which may be the native enzyme purified from *Thermus*
5 *aqueticus* and/or a genetically engineered form of the enzyme synthesised in *E. coli* sold under the trade mark AMPLITAQ. Other commercially available polymerase enzymes include Taq polymerases marketed by Promega or Pharmacia. Another thermostable DNA
10 polymerase that could be used is Tth DNA polymerase obtainable from *Thermus thermophilus*. Concentration ranges of the polymerase may range from 0.5 - 5.0 units per 100 μ l of reaction mixture.

Deoxyribonucleotide triphosphates comprising
15 dATP, dCTP, dGTP and dTTP (i.e. dNTPs) can be utilised in the assay with it being realised that dGTP may be substituted with 7-deaza-2'-deoxy GTP and 7-deaza-2'-deoxy ATP can be substituted for dATP. It will also be appreciated that 2'-deoxy ITP can be substituted
20 for any dNTP. The four dinucleotides may be present in a PCR reaction mixture at a concentration of 20-200 μ M and at a pH of about 7.0.

Any suitable biological buffer may also be utilised in the reaction mixture such as Tris-HCl, or
25 Tricine which can provide a pH in the range of 7.4-8.8. Tris-HCl may provide a pH of 8.3-8.8 at 20°C and Tricine may provide a pH of 8.4. The concentration of buffer may be 10-50 mM in the case of Tris-HCl and around 300 mM in the case of Tricine.

30 The buffer may also comprise a source of Mg^{++} such as $MgCl_2$ which may affect (i) primer annealing (ii) strand dissociation temperatures of both template and PCR product, (iii) product specificity, (iv)
35 formation of primer-dimer artifacts and (v) enzyme activity and fidelity. Taq polymerase may require free Mg^{++} on top of that bound by template DNA, primers and dNTPs. Accordingly the PCR mixture may contain

0.5 - 2.5 mM Mg⁺⁺ over the total dNTP concentration.

The buffer may also include KCl in a concentration of up to 50 mM to facilitate primer annealing.

5 Another optional component may be B-mercaptoethanol in a concentration of 50 mM.

Gelatin or bovine serum albumin (BSA) may also be present in a concentration range of 0.01 - 0.1%.

10 Nonionic detergents such as Tween 20, Triton X-100, or Laureth 12 in a concentration range of 0.05 to 0.1% may also be added to help stabilise the enzyme.

15 The primer components may be present in the PCR reaction mixture at a concentration of between 0.1 and 0.5 μ M. The primer length may be between 18 - 40 nucleotides in length and having 50-60% G and C composition.

20 In the choice of primer it is preferable to have exactly matching bases at the 3' end of the primer but this requirement decreases to being relatively insignificant at the 5' end (this is described in Nucleic Acids Research 19 3058). The preferred primers utilised in this invention have a restriction site and m13 sequence added to the 5' end.

25 The published RhD and Rh CcEe sequence data referred to in Le Van Kim *et al.* Proc Natl Acad Sci USA 89 10925-10929 (1992) and Cherif-Zehar *et al.* Proc Natl Acad Sci 87 6243 (1990) differs by only 44 bases. Using sequence differences in exon 7 specific primers were therefore designed for the PCR^o assay
30 described hereinafter.

35 In the reaction conditions applicable to PCR assay, an initial denaturation step may be carried out between 90-100°C, a subsequent annealing step carried out between 40-60°C and a final extension step may be carried out between 70-75°C. Alternatively the annealing step and extension step may be combined if considered appropriate.

However it will be appreciated that other primers along other regions of the gene could be designed so as to distinguish RhD from Rh CcEe where there is at least one consecutive mismatch in the RhD/CcEe sequence.

In this regard there are two ways of making different size bands which may be detected for example in gel electrophoresis by making one of the gene specific primers longer than the other or by designing one primer further from the common primer. In the present invention either of these situations could apply.

In accordance with the present invention however the PCR assay is designed so that the D and CE amplified fragments are distinguishable and this may be achieved by designing either the forward or reverse primers such that one primer is common (e.g. forward) to both genes and one is unique for either D or CE.

The unique primers may also be juxtapositioned at slightly different positions along the D and CE gene respectively to give different size products. In addition, to further enhance the size difference between the two products, one primer may be artificially extended, for example by the addition of extra M13 sequences.

In an alternative situation instead of distinguishing between the D and CE genes using a size difference as described above it may be possible to tag the primers unique for D and CE with different markers which would give a fluorometric or colourmetric end point detection system. Suitable markers may be fluorescence markers or enzyme markers such as horse radish peroxidase or the biotin/avidin system. These markers may be adaptable to either the CAPTAGENE system as herein described or the Dot Blot Matrix System.

In the PCR assay the concentration of the common primer is preferably less than the respective concentrations of the gene specific primers.

It will also be appreciated that the common
5 primer may be either a forward or reverse primer with the gene specific primers being both reverse or forward respectively.

In the present invention the PCR amplified exon 7 as this exon contained the most divergence between D and CE. It was therefore easier to design primers to
10 this region. However, it is clearly within the scope of the invention to amplify other exons and exon/intron boundary areas to achieve a similar result. For example the other exons and exon/intron
15 boundary areas may be amplified as either additional controls or to give more information about D variants.

In this regard the invention may also be applicable to not only the known sequence for D, but also D variants when the sequences of the D variants
20 become known. In this aspect of the invention primers may then be designed specific for these variants and an analogous PCR assay could be utilised to determine D variant classification relevant to a particular individual.

25 Detection of DNA products within the scope of this invention can be achieved using a number of commercial systems. They mostly rely upon attaching a protein or protein binding site sequence to the end of a primer and by using either a bound antibody
30 (specific for the bound protein) or protein (that binds to the protein binding site) to select amplified DNA fragments. Binding can be done in any vessel or material that can attach DNA or proteins. Most methods deal with detection of only one product
35 however by suitably modifying such methods two or more DNA products could be detected. For example detection of DNA products could be carried out using the AMRAD

CAPTAGENE system which is a commercially available detection system for amplifying specific sequences of DNA using microtitre plate technology. This system requires DNA amplification using oligonucleotide
5 primers one of which is biotinylated and the second of which incorporates a specific 12 bp recognition sequence 5'-GCATGHCTCATT for a double stranded DNA binding protein GCN4 which is a GST fusion protein. Such modifications may include -

- 10 (1) using the GCN4 binding sequence within the common primer - this will allow both D and CcEc fragments to be bound to the wells of the microtitre plate; and
- 15 (2) using different proteins/dyes for each gene specific primer so that detection can be performed quantitatively for each gene fragment. With visible detection, one could use biotin attached to one primer (to be detected with avidin-HRP) and attach another protein/enzyme
20 substrate to the other primer with its own antibody/enzyme detection system and react these enzymes sequentially reading values with a spectrophotometer. If dyes having different fluorescence profiles were attached to individual
25 primers such as the TOTO-1/YOYO-1 and TOTO-3/YOYO-3 fluorescent probes obtained from Molecular Probes Inc., both bands could be read with a UV spectrophotometer (Millipore CytoFluor 235 fluorescence plate reader) by simply changing
30 wavelength. Molecular Probes Inc. also supply dyes having visible absorbance that could be used in a similar way.

It will also be appreciated that electrophoresis gels such as agarose gel electrophoresis or
35 polyacrylamide gel electrophoresis may be utilised for detection of DNA products.

The DNA samples utilised for the PCR assay are suitably purified by any suitable means prior to incorporation in the PCR reaction mix. Any method which purifies DNA from a liquid may be utilised such as commercial purification systems e.g. GENECLEAN (B10101) or MAGIC MINIPREPS available from Promega. A salting out method may also be used. Preferably when obtaining a quantitative assessment of the number of gene copies per cell (ie. 0, 1 or 2) the DNA sample is purified. Human tissue can also be utilised such as whole blood containing leucocytes or hair follicle tissue. Again such tissue samples are preferably purified for quantitative assessment although this may not be necessary in relation to qualitative assessment.

EXPERIMENTAL

The published Rh D and CcEe gene sequences differ by only 44 bases. Using sequence differences in exon 7, a forward primer (gattacgaattcGTAACCGAGTGCTGGGGATT) was designed common to both genes, starting at nucleotide position 947, and reverse primers (taccagattacgaattcATGCCATTGCCGGCTC and gattacgaattcCATTGCCGTTCCAGACA), specific for D starting at nucleotide 1058 and CcEe starting at nucleotide 1053 respectively were also designed. These PCR primers give 155-bp and 146-bp fragments for the D and CcEe genes allowing these products to be distinguished by agarose gel electrophoresis.

The PCR reaction consisted of 50 mmol/L KCl, 10 mmol/L Tris-HCl (pH 9.0 at 25°C), 1% Triton X-100, 2 mmol/L MgCl₂, 0.2 mmol/L each of dATP, dCTP, dGTP, and dTTP in a volume of 50 µL H₂O containing 80 ng forward primer, 120 ng of each reverse primer, 2.5 U Taq polymerase (Promega, Madison, WI) and 50 ng human genomic DNA. It is important that the common forward primer be in reaction limiting amounts for a quantitative result. Standard polymerase chain

reaction (PCR) conditions were one cycle of 94°C for 3 minutes, 56°C for 2 minutes, 72°C for 2 minutes, and 35 cycles of 95°C for 30 seconds, 65°C for 1 minute and a final extension of 72°C for 3 minutes.

5 The PCR results in Fig 1 show either one PCR product (Rh neg) or two PCR products (Rh pos). The CcEe gene product is the lower band (146 bp) and the D gene product is the upper band (155 bp). The number of copies of the D gene can be determined by comparing
10 the intensity of the two bands. The CcEe gene that has two gene copies per cell acts as an internal PCR control (Rh neg; lane 1).

 Therefore, a half intensity of the D band compared with CcEe band predicts a single D gene, a
15 heterozygous carrier of D (lane 2). Likewise, an equal or greater intensity of D band compared with CcEe band (lane 3) indicates two D gene copies, a homozygous carrier for D. In practice, the D band intensity of a homozygote consistently appears
20 slightly stronger than the CcEe band probably because of better priming of the D gene-specific primer. Results were also obtained using whole blood (lane 4) and hair follicles (lane 5).

 There are a number of advantages with RhD
25 genotyping by this PCR method. Firstly, PCR using DNA enables the RhD genotype of an individual to be unambiguously known. Prenatal counselling often involves prediction of fetal Rh type and a precise RhD genotype would allow accurate predictions of fetal RhD
30 status to be made and advised. Other applications of RhD PCR genotyping exist in Rh paternity testing and in family and genetic studies using Rh as an inheritance marker.

 Secondly, unlike serology, the RhD PCR method
35 does not require red blood cells or large quantities of human tissue. In the case of fetal Rh testing this could lead to safer testing, avoiding the need for

percutaneous umbilical blood sampling (PUBS) and the attendant risks of immunisation. RhD PCR typing of a fetus would even be possible using any fetal cell containing DNA such as chorionic villi biopsy or even fetal-derived white blood cells circulating peripherally in the pregnant mother. Another application exists in forensic investigations where materials such as hair, teeth, seminal fluid, or dried blood could potentially be used, virtually independent of age, quantity, and quality.

However, it will be appreciated that none of the prior art referred to above allows a direct determination of whether an RhD positive individual carries 0, 1 or 2 D genes per cell. In regard to previous serological agglutination tests the only information that could be obtained was whether the cells were positive or negative.

The crucial feature of the present invention is that the CE gene can serve as a control and (a) provides a reference point for quantitative D gene measurement and (b) ensures that the PCR for the assay has worked because of the presence of the CE gene as internal control.

Another point of relevance to the present invention is that both D gene and the CE gene are amplified in a single tube PCR.

The invention may also include within its scope a test system or kit for carrying out the above PCR assay. Such kit may include -

- (i) the first gene (e.g. CE gene) as control,
- (ii) primers described above,
- (iii) buffers as described above,
- (iv) polymerase as described above, and
- (v) dNTPs as described above, and optionally
- (vi) three additional controls with the second gene in zero, single and double doses.

Such a kit in a preferred form may be prepared as described below.

Samples of 100 ng of DNA were obtained from (i) a human subject who is RhD negative (i.e. 0 copy number per cell), (ii) a human subject who was RhD positive

From the procedure described above it will be appreciated that a commercial kit could be marketed so as to carry out the detection method of the invention including:

- 5 (i) a solution of appropriate primers;
- (ii) a solution of buffer, dNTP's, MgCl₂ and Taq enzyme;
- (iii) reference standards comprising -
 - 10 (a) a DNA cell extract from one individual indicating the presence of the CE gene in a copy number of least 1 per cell only (e.g. having one CE band and no band present for the D gene);
 - 15 (b) a DNA cell extract from another individual indicating the presence of the CE gene in a copy number of at least 1 per cell as well as the presence of the D gene in a copy number of 1 per cell (e.g. having one CE band and one band present indicating that the individual is RhD positive but of sufficient intensity relative to the CE band to indicate the D gene is present in a copy number of 1 gene per cell;
 - 20 (c) a DNA cell extract from another individual indicating the present of the CE gene in a copy number of at least 1 per cell as well as the presence of the D gene in a copy number of 2 per cell (e.g. having one CE band and another band present indicating that the individual is RhD positive but of sufficient intensity relative to the CE band to indicate that the D gene is present in a copy number of 2 genes per cell).
 - 25
 - 30
 - 35

In the above the word "solution" means each of the respective components are present in the same solution or in different solutions.

Thus when a DNA cell extract is obtained from a patient and if the CE band is amplified but nothing else it will be clear that the patient is RhD negative. If results are obtained corresponding to reference standard (b) or (c) then very quickly not only can the patient be provided with an RhD positive status but the copy number relevant to the D gene can also be readily determined.

The invention may also include within its scope the specific primers referred to above in the experimental section.

In relation to D variants there are two types which are currently known. The first type involves a lesion in the genome which gives a reduced expression of a normal D antigen (termed "weak D"). It is not known how many different types of "lesions" may exist within this type. The second type involves a structural defect on the D antigen which results in part of the D antigen sites or epitopes not being expressed (termed "partial D"). There are at least six categories of the "partial D" and they are categorised as DII, III, IVa, IVb, Va, Vc, VI and VII.

References which discuss these categories are - Lomas *et al.* *Vox Sang* 1989:57 261-264 Lomas *et al.* *Transfusion* 1993 33 535 and Gorick *et al.* *Vox Sang* 1993 65 136-140. All the variant forms within these types could be tested by the PCR single tube assay of the invention once it is known what DNA sequence variations are responsible for each respective variant. Targeted primers could then be made. The CE gene would serve as an internal control to validate the PCR and also as a reference to determine the gene copy number for the D gene. A possible combination of gene copies is indicated in Table 2.

The D variant is really an altered and uncommon form of the D gene. However, it can be of clinical significance.

5 The abovementioned kit could have application in the following areas of transfusion medicine and immunohaematology -

(a) Ante-Natal Counselling clinics:

10 The kit would be used for precise D gene measurement of husbands of Rh D negative wives, especially those sensitized to the D gene from a prior pregnancy.

(b) Blood Grouping Reference Laboratories:

15 The kit determines the precise D gene level and therefore, in combination the Cc and Ee serology typing results allows a determination of the precise genotype.

20 As an example of how this can be done, reference should be made to Table 1 which tabulates the classifications that were obtained by D gene measurement on 102 donors versus the serological predictions. Reference should be made to the corrected genotype which was required in 5 cases and this was on a fairly homogenous and well tested blood donor population. Serological predictions are highly dependent on race origin.

25 (c) Laboratories involved in paternity testing in which precise Rh CDE haplotype combinations are required for putative family members.

30 (d) Forensic laboratories: The PCR assay can be done on blood, hair or other body tissue (please note the assay is at this stage only quantitative for purified DNA).

35 (e) Transfusion Medicine: In cases of massive transfusions before a patients blood group

was performed:- in such cases Rh PCR DNA testing could be the only way a blood group could be obtained - PCR for Cc and Ee would also be needed for this.

- 5 (f) The inability to quantify the number of Rh D genes present means that a true Rh D genotype of an individual could not be assigned.

Reference may also be made to (a) Hyland *et al.*,
10 in Blood, Vol 83, No 2 January 15) 1994 566-572 and
(b) Hyland *et al.*, Blood Vol 84, (1994) which
references are also concerned with RhD genotyping
using PCR whereby the abovementioned PCR method of the
present invention was validated in relation to the D
15 gene dosages. In references (a) and (b) the
assumption that the D gene is not present in RhD
negative cases was tested by appropriate screening of
RhD negative individuals. It was ascertained that
this assumption does not always hold true but
20 nevertheless the accuracy of the detection method of
the invention is over 99%. On rare occasions false
positive results may arise. This will occur for less
than 0.5% for all RhD negative cases. False negative
results may occur for the very rare RD variants e.g.
25 DIV and V variants which occur in less than 0.4% of
the population. Furthermore the clinical significance
of these variants is minimal.

It will also be readily apparent that the method
of the invention may also be applied to exon 10 and
30 exon 4 to 5 of the RhD gene if desired.

TABLE 1

RhD gene measurements among 102 blood donors
Comparison of predicted versus observed D gene levels

5		Serological prediction	no.	Concordant D genotype	Corrected Genotype
		CDe/ce	35	32	3 CDe/cDe
		CDe/CDe	20	19	1 CDe/Ce
10		cDE/ce	14	14	
		ce/ce	14	14	
		CDe/cDE	14	14	
		cDE/cDE	3	2	1 cDE/cE
		ce/cE	1	1	
15		cDe/ce	1	1	
		TOTAL	102	95%	

20 RFLPs determined from Southern analysis using 5' and 3' Rh probes

25

TABLE 2

30	CE	normal D	Variant D (any one of)
	2	0	0
	2	1	0
	2	2	0
	2	0	1
35	2	1	1
	2	0	2*

* most likely

40

CLAIMS:

1. A process for detection of one of a number of closely related genes including the steps of:

- 5 (i) carrying out a PCR assay including one or more DNA test samples from a human, animal or plant DNA cell extract in combination with at least one reference standard which includes a DNA cell extract having a first gene normally found in such DNA cell extract in a copy number of 1 or more per cell and a
10 second gene closely related to the first gene but usually present in the DNA cell extract in a copy number of 0, 1, 2 or more together with a first primer specific for
15 said first gene, a second primer specific for said second gene and a third primer common to both the first gene and the second gene; and
- 20 (ii) determining the presence of the second gene in said DNA test sample(s) by comparison of the test sample(s) with said at least one reference standard.

2. A process as claimed in claim 1 wherein in step (i) there are included as many reference standards to
25 correspond with the variation in copy number of the second gene.

3. A process as claimed in claim 2 wherein there are included in step (i) a plurality of reference standards comprising -

- 30 (a) said first gene and said second gene in a copy number of 0;
- (b) said first gene and said second gene in a copy number of 1;
- 35 (c) said first gene and said second gene in a copy number of 2.

4. A process as claimed in claim 3 wherein step (ii) also includes quantification of the second gene in copy number.

5. A process as claimed in claim 3 used for RhD genotyping wherein the first gene corresponds to the CcEe gene and the second gene corresponds to the RhD gene or an RhD gene variant.

6. A process as claimed in claim 4 wherein a forward primer gattacgaattcGTAACCGAGTGCTGGGGATT was utilised as well as reverse primers taccagattacgaattcATGCCATTGCCGGCTC and gattacgaattcCATTGCCGTTCCAGACA.

7. A test kit which may be used for detection and quantification of one of a number of closely related genes in the process of claim 1 which include -

- (i) a solution of primers comprising said first primer, said second primer and said third primer;
- (ii) a solution of buffer, dNTP's and polymerase enzyme;
- (iii) at least one reference standard comprising a DNA cell extract from one individual indicating the presence of said first gene in a copy number of least 1 per cell and indicating the presence of the second gene in a copy number of 0, 1, 2 or more.

8. A test kit as claimed in claim 7 wherein the reference standards include:

- (a) a DNA cell extract from one individual indicating the presence of said first gene in a copy number of least 1 per cell but excluding the presence of said second gene;
- (b) a DNA cell extract from another individual indicating the presence of the first gene in a copy number of at least 1 per cell as well as the presence of the second gene in a copy number of 1 per cell.

9. A test kit as claimed in claim 8 wherein there is included a further reference standard comprising a DNA cell extract from another individual indicating the presence of the first gene in a copy number of least 1 per cell as well as the presence of said second gene in a copy number of 2 per cell.
10. A test kit as claimed in claim 6 utilized for genotyping when said first gene is the CE gene and the second gene is the D gene.
11. A test kit as claimed in claim 10 including:
- (a) a DNA cell extract from one individual indicating the presence of the CE gene in a copy number of at least 1 per cell but excluding the presence of the D gene;
 - (b) a DNA cell extract from another individual indicating the presence of the CE gene in a copy number of at least 1 per cell as well as the presence of the D gene in a copy number of 1 per cell.
 - (c) a DNA cell extract from another individual indicating the presence of the CE gene in a copy number of at least 2 per cell as well as the presence of the D gene in a copy number of 2 per cell.

1/1




FIGURE 1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 94/00506

A. CLASSIFICATION OF SUBJECT MATTERInt. Cl.⁶ C12Q 1/68, C12N 15/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶ : C12Q 1/68, C12N 15/12 and keywords belowDocumentation searched other than minimum documentation to the extent that such documents are included in the fields searched
AU : IPC as aboveElectronic data base consulted during the international search (name of data base, and where practicable, search terms used)
DERWENT DATABASE: Files WPAT, BIOT: Keywords Polymerase chain reaction, 3rd, Third primer, common primer, heterozygo:, homozygo: zygosity, gene typing, Rhesus blood group, Rhesus positive, Rhesus negative, RhD, STN DATABASE File CA, polymerase Chain reaction, PCR, Rhesus positive, Rhesus negative, Seq GATTACGAATC**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P,X	WO 93/22456 (TRUSTEES OF DARTMOUTH COLLEGE) 11 November 1993 (11.11.93) see whole document	1-4, 7-9
P,X	WO 93/18177 (THE CHILDRENS HOSPITAL OF PHILADELPHIA) 16 September 1993 (16.09.93) see whole document	1-4, 7-9

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
8 December 1994 (08.12.94)

Date of mailing of the international search report

13 Dec 1994 (13.12.94)

Name and mailing address of the ISA/AU

AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION
PO BOX 200
WODEN ACT 2606
AUSTRALIA

Facsimile No. 06 2853929

Authorized officer

M. DONAGHEY

Telephone No. (06) 2832414

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate of the relevant passages	Relevant to Claim No.
P,X	WO 93/18178 (THE CHILDRENS HOSPITAL OF PHILADELPHIA) 16 September 1993 (16.09.93) see whole document	1-4, 7-9
P,X	Blood (1993), 82(5), pages 1682-3, Wolte L. et al. "Rhesus D Genotyping using Polymerase Chain Reaction" see whole document	1-11
Y	The New England Journal of Medicine (1993), Vol. 329, No. 9, pages 607-610, Bennet P.R et al "Prenatal determination of fetal RhD type of DNA amplification" see whole document	1-11
Y	Blood (1991) vol. 78, No. 10, pages 2247-2752, Colin Y et al, "Genetic Basis of the RhD-positive and RhD-negative blood group polymorphism as determined by Southern Analysis see whole document	1-11
X	Derwent WPAT online Abstract Accession No. 92-194019/24, FR 2668162-A1 (LAB EUROBIO) 17 October 1990 (17.10.90)	1-4, 7-9
A	Blood (1993) Vol. 82, No. 2, pages 651-655, Arce M. et al, "Molecular cloning of RhD cDNA derived from a gene present in RhD-positive, but not RhD-negative individuals".	

INTERNATIONAL SEARCH REPORT

Information on patent family members.

International application No.

PCT/AU 94/00506

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member	
WO	9318178	AU	38049/93
WO	9318177	AU	39185/93
WO	9322456		
END OF ANNEX			